GR is not a cancer-specific vulnerability, while MR is. Therefore, GR is not a promising cancer-therapy strategy.
MIYASHI et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: